Alnylam Pharmaceuticals Inc

NASDAQ:ALNY   3:59:59 PM EDT
200.83
-1.88 (-0.93%)
Products, Regulatory

Alnylam Announces Positive Results From APOLLO-B Phase 3 Study Of Patisiran In Patients With ATTR Amyloidosis With Cardiomyopathy

Published: 09/08/2022 06:44 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Presents Positive Results From the Apollo-b Phase 3 Study of Patisiran in Patients With Attr Amyloidosis With Cardiomyopathy.
Alnylam Pharmaceuticals- Patisiran Met Primary Endpoint, Demonstrating Significant Clinical Benefit on Functional Capacity Compared to Placebo at Month 12.
Alnylam - Patisiran Met First Secondary Endpoint, Demonstrating Significant Clinical Benefit on Health Status, Compared to Placebo at Month 12.
Alnylam Pharmaceuticals - Plans to File Snda for Patisiran As Potential Treatment for Attr Amyloidosis With Cardiomyopathy in the U.S. in Late 2022.